The Big Biotech participated in the round to equip Hookipa to advance its cytomegalovirus vaccine and cancer candidate through early clinical testing.
A new form of CRISPR/Cas9 activates specific genes without making breaks in the DNA, which can reduce harmful side effects.
When payers and biopharma fight over pricing, patients with rare diseases can suffer. See how Real World Evidence and value-based contracts can help.
Roche is uncovering data from a Tecentriq trial in bladder cancer patients that could provide clues to countering resistance to checkpoint inhibitors.
An experimental PARP med bought up as part of Pfizer’s multibillion-dollar Medivation buyout performed well in a late-stage trial.
The IPO sets Denali up to push drugs against Alzheimer’s and Parkinson’s diseases through early clinical trials.
Survival in patients who received eryaspase on top of low-dose cytarabine was no longer than that for the group that just got chemotherapy alone.
AZ research exec Johnson jumps to Goldfinch, Human Longevity undergoes C-suite earthquake, Biogen poaches Takeda exec as CIO.
Gilead has made a bolt-on acquisition of Cell Design with an eye to the future of CAR-T.
Orbimed is one of the biggest backers of life science companies in the world with $14 billion in asset management, but today its founder, Sam Isaly, has left…
Juno Therapeutics, which dumped its lead CAR-T program in March, has inked license agreements with Eli Lilly, OncoTracker and Fred Hutch.